Microbot Medical Inc (NASDAQ:MBOT) Director Yoav Zvi Waizer bought 10,000 shares of the stock in a transaction on Monday, December 4th. The shares were acquired at an average cost of $1.10 per share, for a total transaction of $11,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $11,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Microbot Medical Inc (MBOT) traded down $0.02 during trading on Wednesday, reaching $1.08. 427,700 shares of the company’s stock traded hands, compared to its average volume of 885,388. Microbot Medical Inc has a 52-week low of $1.00 and a 52-week high of $9.94.

A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. grew its holdings in Microbot Medical Inc (NASDAQ:MBOT) by 252.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 159,992 shares of the biotechnology company’s stock after purchasing an additional 114,561 shares during the quarter. Vanguard Group Inc. owned about 0.43% of Microbot Medical worth $228,000 as of its most recent filing with the SEC. 4.72% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/06/yoav-zvi-waizer-acquires-10000-shares-of-microbot-medical-inc-mbot-stock.html.

About Microbot Medical

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Insider Buying and Selling by Quarter for Microbot Medical (NASDAQ:MBOT)

Receive News & Ratings for Microbot Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.